Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012
Spectra Intelligence, November 2005, Pages: 91
Examines the global mood disorder sector and highlights the converging market stimulators and inhibitors that may lead to a market decline from an estimated US$17.4 billion in 2005 to US$15 billion in 2012. Key factors discussed include patent expirations of leading antidepressants over the next 7 years, increased generic substitution trends, safety concerns over SSRIs; cost-containment in prescribing; and litigation activities between research-based and generic companies. Key market stimulators identified to buffer the decline include the introduction of new drug classes, new formulations, line extensions, increased patient populations, and treatment resistance. The report also evaluates the emerging market sector of cognitive and memory impairment and shows the extent of R&D activities within the field. Analysis of both sectors reveals candidates that have top-line earning prospects and also provides an insight into potential licensing or acquisition opportunities in promising psychopharmacotherapy market subsectors.
Objectives of the Report
The objectives of this report are to provide a detailed analysis of the global psychopharmacotherapeutic market related to mood disorders and cognitive impairment. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. It is hoped that the reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.
Research Methodology
The contents of this report are derived from in-depth research-based surveys of the industry and proprietary analytical assessment tools. Source material also comprises the following:
- Company information
- Personal communication
- Trade press articles
- News releases
- Internet-based research
- Library research
- Scientific periodicals
- Product information
- Market analyst data
- Public information datasets
- Conference proceedings
- Medical/pharma associations
REPORT HIGHLIGHTS AND KEY FINDINGS
- Pharmacotherapies indicated for mood disorders account for a market valued at US$17.4 billion, which is forecast to decrease 13.6% CAGR to US$15 billion by 2012
- Critical analysis of depression, anxiety disorders, and cognitive and memory impairment
- Review of epidemiological, aetiological, and therapeutic data for key therapy areas
- Analysis of 10 marketed products and inclusion of 88 R&D candidates identified in preclinical to clinical stages of development for depressive illnesses and cognitive impairment
- Sales estimates (US$) to 2012 for major therapy areas
- Strategic insights for life-cycle optimization and product development
- Critical evaluation of leading antidepressants
- Emerging markets identified and sector analysis
- Trend analysis of industry events and activities over past 2 years
- Detailed R&D themes and clusters by therapy area
- Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
- High revenue-yielding prospects identified with projected sales estimations
- R&D pipeline positioning for key therapy areas
- Market insights for product development and drug promotion
WHAT CAN I LEARN FROM THIS REPORT?
- Which antidepressants are the current and potential future market leaders
- Insight into the main psychopharmacotherapies for depression and anxiety disorders
- How companies optimize product life cycle through supplementary indications and
reformulation
- Which premarket antidepressants are identified as potential blockbusters
- Which companies are developing drugs for cognitive impairment and memory deficits
- Sales predictions to 2012 for leading antidepressants/anxiolytics
- What the likely impact of pipeline products will be on value growth over the next decade
- Which generic defence strategies are being employed by research-based companies
- How generic companies are becoming increasingly litigious in advance of patent expiry
- Which therapy subsectors could be niche market opportunities for depressive illnesses
- What the future outlook could be for marketed antidepressants and anxiolytics
- Insight into R&D trends for antidepressants, and drugs for cognitive impairment
- Which molecules and compounds are main R&D clusters
- What are the top prospects for mood disorders, cognitive impairment, and memory deficits over the next decade and to 2020?
Plus Many Other Insights, Observations, Assumptions, and Predictions to be Garnered…
List of Tables
List of Figures
Executive Summary
Objectives of the Report
Research Methodology
Chapter 1 Introduction to Mood Disorders and Cognitive Impairment
Depression
Prevalence
Aetiology of Depression
Types of Depression
Major depression
Dysthymia
Bipolar Disorder
Symptoms of Depression
Anxiety Disorders
Prevalence
Cognitive Impairments and Memory Deficits
Prevalence
Pharmacotherapy for Cognitive Impairment
Chapter 2 The Global Market for Mood Disorders: Depression and Anxiety
Mood Disorders: Depression and Anxiety
Market Overview of Drugs to Treat Depression and Anxiety Disorders
Market Analysis and Insights for Drugs to Treat Depressive Illnesses
Market Analysis: Antidepressant Therapy Area
Prozac (Fluoxetine) - Eli Lilly
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Cymbalta (Duloxetine) - Eli Lilly/Boehringer Ingelheim
Product Overview
Indications and Supplementary Labelling
Sales Prospects
Commercial Outlook
Zoloft/Lustral (Sertraline) - Pfizer
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Seroxat/Paxil/Deroxat (Paroxetine) - GlaxoSmithKline
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Wellbutrin (Bupropion) - GlaxoSmithKline
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Effexor (Venlafaxine) - Wyeth
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Remeron/Zispin (Mirtazapine) - Organon/Akzo Nobel
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Cipramil/Celexa (Citalopram) - Lundbeck/Forest Laboratories
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Cipralex/Lexapro (Escitalopram) - Lundbeck/Forest
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Future Considerations and Market Insights for the Antidepressant Market
Pipeline Antidepressants
Pipeline Focus
Valdoxan (Agomelatine) - Servier
Pharmacotherapeutics for Cognitive Impairment and /Memory Deficits
Future Market Focus - Age-Related Cognitive Decline
Nootropil (Piracetam) - UCB Pharma
Companies Developing Drugs for Cognitive and Memory Impairment
EGb 761/Tanakan - Ipsen
Chapter 3 Drugs in Research and Development
Pipeline Mood Stabilizers and Drugs for Cognitive Impairment
Drugs in Development for Mood Disorders: Antidepressants and Anxiolytics
Depression and Anxiety: Research and Development Overview
Drugs in Development for Cognitive and Memory Impairment
Cognitive/Memory Impairment - Research and Development Overview
Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining
Data Analysis, Therapy Forecasting, and Prospect Mining
Market Analysis and Therapy Forecasting
Antidepressants and Anxiolytics
Therapy Area Forecasts
Comparative Analysis: Antidepressant/Anxiolytic Product Sales
Prospect Mining
Mood Disorders: Depression and Anxiety
Cognitive and Memory Impairment
Therapy Area Forecasts, 2012 and 2020
Chapter 5 Report Synopsis
Depressive/Anxiety and Cognitive/Memory Impairment - Key Data Points
Bibliography and Reference Sources
List of Tables
Table 1.1 Role of Neurotransmitters in Depression
Table 1.2 Symptoms of Depression and Bipolar Disorder/Mania
Table 1.3 Major Anxiety Disorders
Table 1.4 Causes of Dementia
Table 2.1 Estimated Global Sales & Forecasts of Leading Antidepressants, 2004-2012 (US$m)
Table 2.2 Estimated Annual Growth Rates of Leading Antidepressants (%), 2004-2012
Table 2.3 Leading Antidepressants Ranked by Sales, 2005 & 2012
Table 2.4 Primary and Secondary Indications for Antidepressants
Table 2.5 Estimated Sales (US$) and Annual Growth (%) of Prozac, 2005-2012
Table 2.6 Estimated Sales (US$) and Annual Growth (%) of Cymbalta, 2005-2012
Table 2.7 Estimated Sales (US$) and Annual Growth (%) of Zoloft, 2005-2012
Table 2.8 Estimated Sales (US$) and Annual Growth (%) of Seroxat/Paxil, 2005-2012
Table 2.9 Estimated Sales (US$) and Annual Growth (%) of Wellbutrin, 2005-2012
Table 2.10 Estimated Sales (US$) and Annual Growth (%) of Effexor, 2005-2012
Table 2.11 Estimated Sales (US$) and Annual Growth (%) of Remeron, 2005-2012
Table 2.12 Estimated Sales (US$) and Annual Growth (%) of Cipramil/Celexa, 2005-12
Table 2.13 Estimated Sales (US$) and Annual Growth (%) of Cipralex/Lexapro, 2005-12
Table 2.14 Drugs in Development for Cognitive and Memory Impairment, 2005 (partial)
Table 3.1 Drugs in Development for Depression and Anxiety, 2005
Table 3.2 Drugs in Development for Cognitive and Memory Impairment, 2005
Table 4.1 Global Drug Market for Antidepressants and Anxiolytics (US$m) 2004-2012
Table 4.2 Therapy Area Forecasts for the Global Mood Disorders and Cognitive Impairment Market Sectors, 2012 and 2020
List of Figures
Figure 2.1 Estimated Global Sales of Leading Antidepressants, 2005 & 2012
Figure 2.2 Estimated Market Share of Leading Antidepressants, 2005 & 2012
Figure 4.1 Therapy Area Forecasts for Antidepressants and Anxiolytics, 2005 & 2012 (US$m)
Figure 4.2 Comparative Analysis of Leading Antidepressants and Anxiolytics 2004-2012
Figure 4.3 Key Antidepressant/Anxiolytic Prospects in the CNS Development Pipeline, 2005
Figure 4.4 Key Cognitive and Memory Impairment Prospects in the CNS Development Pipeline, 2005
Psychopharmacotherapies prescribed for mood disorders account for approximately 26% of the world CNS market. This mature market sector is estimated at US$17.4 billion for 2005 but is forecast to decrease 13.6% to US$15 billion by 2012. There are several reasons for a predicted downward shift in product revenues which, according to Spectra, includes patent expirations of leading antidepressants over the next 7 years, increased worldwide generic substitution, safety concerns over SSRIs; and cost containment in prescribing. However, major revenue losses for some products will be offset by the introduction of new drug classes, new formulations, line extensions, increased patient populations, and treatment resistance.
Generics companies are showing signs of increasing litigious activity in the antidepressant domain and loss of market exclusivity either through natural patent expiry or unsuccessful patent litigation are continuing to be major obstacles facing research-based companies. However, generic defense strategies for research-based companies may be transitioning to partnering with rather than opposing generic firms.
Despite challenges for the pharmaceutical industry in relation to centrally acting drugs to treat depressive disorders, novel drugs such as Valdoxan that offer unique advantages over other antidepressants in addition to positive effects on circadian rhythms show great promise for high value and volume sales on approval and launch. With over 80 drugs in development for depressive illnesses and cognitive impairment comprising sophisticated reuptake inhibitors, neuropeptide agonists, antagonists, and receptor modulators, the future of this psychopharmacology sector is predicted to transition to a highly changeable market segment that will lead to both winners and losers along the way.
Although a downward shift is forecast in market value for the global psychopharmacotherapeutic market in relation to mood disorders, several opportunities are identified including treatment-resistant depression and cognitive impairment. In particular, age-related cognitive decline is an untapped neuropsychological area that has been flagged by Spectra as a potential blockbuster market of the future. Drugs to prevent cognitive impairments such as forgetfulness, treat impairments in thought-processing or improve cognitive function such as memory or learning are a new focus of drug development that may not be restricted to neurodegenerative diseases, and successful commercialization with indications also in the life enhancement realm may expand the CNS market considerably over the next decade and beyond.
In this report, Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012, the reader will be introduced to CNS therapy areas of depressive disorders and cognitive impairment that are identified as highly dynamic market sectors that will continue to evolve over the next decade based on new antidepressants, line extensions, and
newly created indications and market sectors.
The report provides a detailed analysis of the therapy areas to include insights for product extension and optimization, sales forecasts to 2012, and impact of late-stage antidepressants. Therapy area segments conclude with a summary of the key issues that are considered to affect growth and sustainability. An overview of R&D programs within the field is also highlighted showing products from preclinical to premarket authorization phases of development. Promising agents are discussed in relation to development status and commercial prospects.
Therapy area forecasting and illustrative market data and analysis is also presented to provide an insight into top-performing products and sales estimates to 2012. Therapy forecasting to 2020 is also presented to enable the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modeling.
Companies Mentioned
ABIOGEN
ABRIKA PHARMACEUTICALS
ALPHAPHARM
ALPHARMA
AMARIN
ANCHEN PHARMACEUTICALS
ANTARES PHARMA
APOTEX
ASTRAZENECA
BARR LABORATORIES
BENTLEY PHARMACEUTICALS
BIOVAIL
BOEHRINGER INGELHEIM
BRISTOL-MYERS SQUIBB
BTG
CARACO PHARMACEUTICAL
LABORATORIES
CEPHALON
CIMA LABS
CIPLA
COLLEGIUM PHARMACEUTICALS
CORTEX PHARMACEUTICALS
CYPRESS BIOSCIENCE
DOV
DR REDDY'S LABORATORIES
EON LABS
ENHANCE BIOTECH
FABRE-KRAMER PHARMACEUTICALS
FOREST LABORATORIES
GENAISSANCE PHARMACEUTICALS
GLAXOSMITHKLINE
HELICON THERAPEUTICS
HEXAL
IMPAX LABORATORIES
IPSEN
IVAX
JOHNSON & JOHNSON
LILLY
MERCK
MEMORY PHARMACEUTICALS
MYLAN LABORATORIES
NEUROCRINE
NEUROGEN
NEUROSEARCH
NEURO3D
NOVARTIS
ONO PHARMACEUTICALS
ORGANON
PENTECH PHARMACEUTICALS
PFIZER
PHARMACEUTICAL RESOURCES
PHARMOS
PHERIN PHARMACEUTICALS
PREDIX
PRESCIENT NEURO-PHARMA
ROCHE
SAEGIS PHARMACEUTICALS
SEPRACOR
SHIONOGI
SPECTRUM PHARMACEUTICALS
SYNTHON PHARMACEUTICALS
SANOFI-AVENTIS
SENTION PHARMA
SERVIER
SK PHARMA
SKYEPHARMA
SOLVAY PHARMACEUTICALS
SOMERSET PHARMACEUTICALS
TAISHO
TARGACEPT
TETRAGENEX
TEVA PHARMACEUTICAL
TORPHARM
LUNDBECK
UCB PHARMA
VANDA PHARMACEUTICALS
VELA PHARMACEUTICALS
WATSON PHARMACEUTICALS
WYETH
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
